New cardinal health report examines shifts in biosimilars industry

Study reveals provider perceptions of commercially available biosimilars and anticipated launches, which have the potential to increase equitable access to critical treatments   dublin, ohio , feb. 22, 2023 /prnewswire/ -- today, cardinal health (nyse: cah) released its 2023 biosimilars report: tracking market expansion and sustainability amidst a shifting industry, a publication that highlights provider perceptions, utilization and the latest market trends of biosimilars. the report assesses new and changing perspectives regarding some of the most disruptive biosimilars launched in the areas of immunology and ophthalmology, noting a growing familiarity of the medications among rheumatologists with 76% reporting being very familiar with the products, a 43% jump year-over-year.
CAH Ratings Summary
CAH Quant Ranking